Sugi Predict

Sugi Predict / Compounds / SCHEMBL1404944

SCHEMBL1404944

SCHEMBL1404944

CC(=O)/C=C/c1ccc(Cl)cc1Cl

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.63
▸ ALDH1A1 P00352 5/20 0.63
▸ KDM4E B2RXH2 3/20 0.63
▸ L3MBTL1 Q9Y468 2/20 0.63
▸ GAA P10253 1/20 0.63
▸ RAB9A P51151 4/20 0.62
▸ NPC1 O15118 3/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ POLB P06746 1/20 0.62
▸ LMNA P02545 6/20 0.55
▸ KMT2A Q03164 6/20 0.55
▸ MAOB P27338 1/20 0.55
▸ MEN1 O00255 4/20 0.54
▸ CTDSP1 Q9GZU7 1/20 0.54
▸ PTPN5 P54829 1/20 0.52
▸ PKM P14618 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404946 1.00 MAPT (0.63) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL30377588 1.00 MAPT (0.63) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL31356854 1.00 MAPT (0.63) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL7687333 0.85 MAPT (0.46) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL7687335 0.85 MAPT (0.46) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL14926715 0.84 GABRA1 (0.50) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL29419102 0.83 MAPT (0.65) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL481451 0.83 MAPT (0.65) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL1193408 0.83 MAPT (0.65) MAPTALDH1A1KDM4EL3MBTL1GAA
SCHEMBL165227 0.83 MAPT (0.65) MAPTALDH1A1KDM4EL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113620901-B Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof 杭州师范大学 2023-02-10 — — CN claimed
CN-109652463-A A method of using Perakine reductase synthesis of chiral alcohol 浙江大学 2019-04-19 — — CN claimed
WO-1999052936-A2 ARGININE PEPTIDE ANALOGS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS EISAI CO., LTD. (JP) 1999-10-21 — — WO claimed
CN-113620901-B Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof 杭州师范大学 2023-02-10 — — CN disclosed
CN-109652463-B Method for synthesizing chiral alcohol by using Perakine reductase 浙江大学 2020-05-08 — — CN disclosed
CN-109652463-A A method of using Perakine reductase synthesis of chiral alcohol 浙江大学 2019-04-19 — — CN disclosed
EP-1783115-B1 ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE INST MATERIA MEDICA CAMS (CN) 2016-07-13 — — EP disclosed
WO-2015022335-A1 VANCOMYCIN ANALOGS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2015-02-19 — — WO disclosed
EP-2488501-B1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-04-30 — — EP disclosed
EP-2488501-B1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-04-30 — — EP disclosed
US-8524744-B2 preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2013-09-03 — — US disclosed
US-20070112015-A1 Substituted dihydropyridines and methods of use CHEMOCENTRYX, INC. (US) 2007-05-17 — — US disclosed
US-20070112015-A1 Substituted dihydropyridines and methods of use CHEMOCENTRYX, INC. (US) 2007-05-17 — — US disclosed
EP-1783115-A1 ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2007-05-09 — — EP disclosed
WO-2007051062-A2 SUBSTITUTED DIHYDROPYRIDINES AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-05-03 — — WO disclosed
WO-1999052936-A2 ARGININE PEPTIDE ANALOGS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS EISAI CO., LTD. (JP) 1999-10-21 — — WO disclosed
EP-0036718-B1 7-CHLORO-3-SUBSTITUTED ARYL-3,4-DIHYDRO-1,9(2H,10H) AND 10-HYDROXY ACRIDINEDIONEIMINES, PROCESSES FOR PRODUCING THE ACRIDINEDIONEIMINES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE ACRIDINEDIONEIMINES WARNER-LAMBERT COMPANY (US) 1985-01-02 — — EP disclosed
EP-0036718-A2 7-Chloro-3-substituted aryl-3,4-dihydro-1,9(2H,10H) and 10-hydroxy acridinedioneimines, processes for producing the acridinedioneimines, and pharmaceutical compositions containing the acridinedioneimines WARNER-LAMBERT COMPANY (US) 1981-09-30 — — EP disclosed
US-4291034-A 7-Chloro-3-substituted aryl-3,4-dihydro-1,9(2H,10H) and 10 hydroxy acridinedioneimines having antimalarial activity WARNER LAMBERT COMPANY (US) 1981-09-22 — — US disclosed
US-3989708-A HYPOTENSIVE, CORONARY VESSEL DILATORS BAYER AKTIENGESELLSCHAFT (DT) 1976-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112015-A1 Substituted dihydropyridines and methods of use C3AR1, C5AR1, C5AR2 MAPT 4656/4885ALDH1A1 1488/4885KDM4E 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.